Comparison of the pancreatic and hepatic glucokinase gene transcripts reveals tissue-specific control of expression and the existence of two distinct promoters in a single glucokinase gene. The existence of alternate promoters suggests that separate factors regulate glucokinase transcription in the two tissues. Hepatic glucokinase expression has been shown to be repressed by cAMP; however, in the pancreatic ␤-cell it is unlikely that cAMP represses glucokinase activity, as cAMP is known to positively affect glucose-induced insulin secretion, a process that in mature islets requires pancreatic glucokinase activity. In this work we demonstrate that cAMP indeed has a stimulatory effect on pancreatic glucokinase. The cyclic nucleotide stimulates pancreatic glucokinase activity after 3-h incubation, and maximal effects are observed after 6 and 12 h of treatment. Using the bDNA assay, a sensitive signal amplification technique, we detected relative increases in glucokinase messenger RNA levels of 40.5 Ϯ 7.5% after 3-h incubation with cAMP. This stimulatory effect was increased to 106.3 Ϯ 22% after 6-h incubation and sustained up to 12 h of incubation. Inhibition of gene transcription by actinomycin D abolishes cAMP-induced glucokinase activity. In transfected fetal islets, cAMP increased the activity of the Ϫ1000 bp rat glucokinase promoter by 60 Ϯ 6%. These data demonstrate that cAMP has a stimulatory effect on pancreatic glucokinase gene expression and that the nucleotide has opposite effects on pancreatic and hepatic glucokinase, supporting the concept that glucokinase transcription in the liver and that in the ␤-cell differ.
G LUCOKINASE (EC 2.7.1.1) is a tissue-specific enzyme present in hepatocytes, pancreatic ␤-cells, and certain neuroendocrine cells of the brain and gut (1) (2) (3) (4) (5) . Glucokinase plays a key role in glucose homeostasis, regulating insulin secretion in response to glucose in the ␤-cells (6, 7) and uptake of glucose in the liver (8, 9) . In humans, mutations in the glucokinase gene cause maturity-onset diabetes of the youth (10) or hyperinsulinemia (11) .
Comparison of the pancreatic and hepatic glucokinase gene transcripts reveals a tissue-specific control of their expression as well as the existence of two distinct promoters in a single glucokinase gene (12, 13) . The existence of alternate promoters suggests that separate factors regulate glucokinase transcription in the two tissues. In the liver, glucokinase activity is regulated at the level of gene transcription in response to fasting and refeeding (14) , with insulin and glucagon serving as the mediators of this response (15) (16) (17) . In contrast, in pancreatic ␤-cells, glucose levels modulate glucokinase activity (2, 18, 19) , and this modulation apparently occurs through posttranscriptional mechanisms (19) . This difference might be expected considering the different functions of these two tissues in glucose homeostasis. In previous reports we have also demonstrated that pancreatic glucokinase transcription and activity are regulated by several hormones and vitamins, and that this hormonal regulation differs in hepatic and pancreatic genes (20 -22) .
In the liver glucokinase gene transcription is decreased by glucagon through increases on cAMP (15, 17, 23) . This effect is consistent with the role of glucagon favoring gluconeogenesis and glycogenolysis. However, in the pancreatic ␤-cell it is unlikely that cAMP represses glucokinase activity, because cAMP is known to positively affect glucose-induced insulin secretion, a process that in mature islets requires pancreatic glucokinase activity (24 -26) . In this work we investigated the effect of cAMP on glucokinase enzyme activity and gene expression. We chose pancreatic fetal islets because of their high percentage of ␤-cell yield, their capacity to be transfected with the glucokinase promoter, and the lesser amount of time required for their isolation compared with the adult islets.
Materials and Methods

Fetal islet culture
Twenty-one-day-gestation fetal Wistar rat islets were isolated as described previously (27) . Briefly, pancreatic glands obtained from four to six rats were finely minced and digested with collagenase type D and 2 l deoxyribonuclease I (Roche Molecular Biochemicals, Mannheim, Germany). The washed digest was suspended in RPMI 1640 medium containing 10% FBS, 11 mm glucose, 400 U/ml penicillin, and 200 mg streptomycin (Life Technologies, Inc., Gaithersburg, MD; supplemented RPMI 1640 medium) and distributed equally into two 60-mm tissue culture dishes (Costar, Cambridge, MA). Cultures were incubated for 5 h at 37 C in a humidified atmosphere of 5% CO 2 to deplete them of fibroblasts. Islets were then seeded into 60-mm tissue culture dishes (Costar, Cambridge, MA) and treated either with 8-bromo-cAMP (Sigma, St. Louis, MO) or vehicle (RPMI 1640) at the concentrations and times indicated in the text. In experiments in which RNA synthesis was inhibited, islets were preincubated with or without actinomycin D1 at a concentration of 5 g/ml for 1 h and then treated either with 8-bromocAMP (10 Ϫ4 m) or vehicle (RPMI 1640) for 3 h.
Glucokinase assay
Islets from five or six pancreases, were harvested and centrifuged at 1200 rpm. Tissue pellets were lysed in 500 l reporter lysis buffer (Promega Corp., Madison, WI) and vortexed, and cell membranes were disrupted by three freeze-thaw cycles. Five hundred microliters of GK buffer consisting of 50 mm Tris (pH 7.6), 4 mm EDTA, 150 mm KCl, 4 mm Mg 2 SO 4 , and 2.5 mm dithiothreitol were added. The lysates were then centrifuged at 4 C for 1 h at 35,000 ϫ g in an ultracentrifuge (model Optima, Beckman Coulter, Inc., Palo Alto, CA). Supernatants were recovered, and enzymatic activity was assayed as described previously by Walker and Parry (28), using NAD (Sigma) as the coenzyme. Glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides (Sigma) was used as the coupling enzyme. Correction for low hexokinase activity was applied by subtracting the activity measured at 0.5 mm glucose from the activity measured at 100 mm glucose. Protein concentrations were determined by Bradford assay (29) .
Messenger RNA (mRNA) analysis
Glucokinase and actin mRNA were quantified using branched DNA (bDNA) technology in a 96-microwell format as previously described for quantification of insulin pre-RNA and glucokinase (21, 30) . All components, including buffers and DNA reagents, were obtained from Chiron Corp. (Emeryville, CA). RNA was extracted by either TRIzol (Life Technologies, Inc.) or cell lysis with 400 l extraction buffer [78 mm HEPES (pH 8.0), 12.5 mm EDTA (pH 8.0), 6.27 mm LiCl, 1.6 lithium lauryl sulfate, proteinase K (1 mg/ml), single stranded DNA (19 g/ml), 7.8% formamide, 0.05% sodium azide, and 0.05% Proclin 300]. RNA samples were mixed with 200 l extraction buffer along with proteinase K and glucokinase capture and label probes, loaded in the microwell plate, sealed with an adhesive-backed mylar plate sealer (Microtiter Plate Sealer, Flow Laboratory, Rockville, MD), and incubated overnight at 63 C in a plate heater to capture the targeted nucleic acids to the oligonucleotidemodified microwell surface. After cooling at room temperature for 10 min, cells were washed twice with wash A (Chiron Corp.). Fifty microliters of branched DNA (bDNA) amplifier solution containing the bDNA amplifier probe at 1 pmol/ml in amplifier diluent (Chiron Corp.) were added and hybridized at 53 C for 30 min. After cooling and washing as described above, 50 l of a mixture containing alkaline phosphatase-conjugated label probes (2 pmol/ml) in label diluent (Chiron Corp.) were added and hybridized at 53 C for 15 min. The plate was cooled and washed twice in buffer A as described above and then washed three times with wash solution B (Chiron Corp., Emeryville, CA). Finally, 50 l chemiluminescent substrate (Lumiphos 530), an enzyme-triggered dioxetane substrate for alkaline phosphatase, were added, and the plate was incubated at 37 C for 25 min. Light emission was measured in a luminometer at 37 C. Each sample was assayed in triplicate and standardized to actin mRNA.
Plasmid constructs
The construction of pFOXCAT1 has been described previously (31) . The rat ␤-cell glucokinase 1000 promoter extends from Ϫ1000 to ϩ14 bp and was a gift from M. Magnuson (Vanderbilt University, Nashville, TN) (32) . The simian virus 40-luciferase pGL3-Control vector (Promega Corp.) was donated by Dr. E. Garrido (National Polytechnique Institute) and Dr. F. Ló pez-Casillas (National University of México, México City, México).
Fetal islet transfection
Experiments were performed as previously described by German et al. (33) ; briefly, 21-day-gestation fetal Wistar rat islets were isolated and digested for 5 min with collagenase type P and 2 l deoxyribonuclease I (Roche). After 3 h of plating to deplete fibroblasts, islets were recovered and dispersed with 0.05% trypsin and 0.53 mm EDTA (Life Technologies, Inc.). Dispersed islets were incubated at 37 C in a humidified atmosphere of 5% CO 2 after 3 h of plating to deplete culture of fibroblasts, then cells were harvested by rinsing the plates, pelleted, washed twice in room temperature PBS, resuspended in 0.8 ml PBS with 25 g double cesiumpurified plasmid DNA, and electroporated with a discharge of 175 V and 2000 farad in a BTX electroporation system model 600 (San Diego, CA). In cotransfection experiments 12.5 g simian virus 40-luciferase vector were also added. The transfected cells were grown in supplemented RPMI containing 11 mm glucose with 8-bromo-cAMP (10 Ϫ4 m) or vehicle (RPMI 1640) for approximately 48 h before harvesting and protein extraction. Chloramphenicol acetyltransferase (CAT) TLC was performed using 25 g protein, and to generate enough CAT product, the sample was incubated for 3 h. CAT signals were analyzed using a PhosphorImager 425 (Molecular Dynamics, Inc., Costa Mesa, CA) or were counted in a scintillation counter (Minamaxi-␤ Tri-carb, United Technologies, Packard, Meriden, CT). A commercial kit was used to measure luciferase activity (Promega Corp.).
Statistics
Data are presented as the mean Ϯ se. Individual comparisons were evaluated by Student's paired two-tailed t test. Multiple comparisons were evaluated using one-way ANOVA. The significance level chosen was P Ͻ 0.05.
Results
cAMP effect on glucokinase activity
We investigated the effects of different concentrations of cAMP on glucokinase activity in islets isolated from 21-day fetal rats. As shown in Fig. 1 , 24-h incubation with cAMP 
concentrations as low as 10
Ϫ5 m increased glucokinase activity significantly by 22 Ϯ 4.8% (P Ͻ 0.05), and a cAMP concentration of 10 Ϫ4 m produced a maximal increase (176.9 Ϯ 6.6%). No further increase was achieved by a concentration of 10 Ϫ3 m. In the same experimental model we assessed the time course of cAMP effect. As shown in Fig. 2 , a cAMP concentration of 10 Ϫ4 m increased glucokinase activity significantly (50.3 Ϯ 20.2%; P Ͻ 0.05) after 3-h incubation. Greater increases of 116.5 Ϯ 40% and 140.6 Ϯ 17% were observed at 6 and 12 h of treatment, respectively. After 24-h incubation, the stimulatory effect of the cyclic nucleotide was only 76.9 Ϯ 6.6%. A similar positive effect of cAMP on glucokinase activity was observed in both cultured adult islets and in RIN-m5F insulinoma cells (data not shown).
cAMP effect on glucokinase mRNA levels
We determined whether the stimulatory effect of cAMP on glucokinase activity was related to an increase in glucokinase gene expression. Because glucokinase mRNA levels are low, we adapted the bDNA assay, a sensitive signal amplification technique (21, 30) , to measure glucokinase mRNA levels. Each sample was standardized to actin, a constitutive mRNA that was not modified by the treatment. A cAMP concentration of 10 Ϫ4 m for 3 h produced a relative increase of 40.5 Ϯ 7.5% in glucokinase RNA levels; this stimulatory effect was increased to 106.3 Ϯ 22% at 6 h of incubation and was sustained up to 12 h of incubation with the nucleotide (103 Ϯ 15%). The effect was reduced to 41 Ϯ 7.2% at 24 h (Fig. 3) .
To determine whether the rapid increase in glucokinase activity in response to cAMP was related to the increase observed in its mRNA levels, we analyzed glucokinase activity in islets in which gene transcription was inhibited by actinomycin D. As shown in Fig. 4 , the increase in glucokinase activity was prevented by the inhibitor. Microscopic analysis showed that the treatment with actinomycin did not affect the viability of the islets (data not shown).
Effect of cAMP on glucokinase promoter activity
A construct containing Ϫ1000 kb of pancreatic glucokinase promoter driving the CAT reporter gene was transfected into primary cultures of fetal islets. Treatment with 10 Ϫ3 m cAMP for 48 h increases glucokinase promoter activity by 60 Ϯ 6% (Fig. 5) . cAMP has no effect on the empty pFOX-CAT1 vector containing no promoter upstream of the CAT reporter gene. In cotransfection studies with a vector containing luciferase gene to correct for transfection efficiency, similar cAMP effects were observed (pFOX-CAT, 1.5 Ϯ 10.5%; Ϫ1000 kb, 76.5 Ϯ 10%; n ϭ 2).
Discussion
In the present study we demonstrate that cAMP stimulates pancreatic glucokinase gene expression and glucokinase enzyme activity. This stimulatory effect of cAMP on pancreatic glucokinase is in contrast to the repressive effect of cAMP on hepatic glucokinase (15, 17, 23) . This difference is in agreement with the different roles of cAMP in these two tissues. In the liver, cAMP mediates the effects of glucagon, which stimulates glucose production by the liver and therefore opposes the glucose catabolic pathways involving glucoki- nase. In contrast, in the ␤-cell cAMP increases insulin secretion, a process that in mature islets is dependent on glucokinase.
The effect of cAMP on glucokinase is observed within 3 h of incubation with cAMP and peaks around 12 h. The facts that the rapid effect of cAMP on pancreatic glucokinase activity was paralleled by an increase in glucokinase mRNA levels, and that inhibition of mRNA synthesis by actinomycin suppresses the stimulatory effect of cAMP on glucokinase activity suggest that cAMP exerts its effect through the stimulation of pancreatic glucokinase gene expression. The positive effect of cAMP on glucokinase activity and mRNA levels was also observed in adult islets and in RINm5F (data not shown). The similar response of cAMP in fetal and adult islets is in agreement with previous observations (21, 34) , indicating that glucokinase responds in a similar manner to different agents in fetal and in adult islets. Our results contrast with a previous report of Hinata et al. (35) that cAMP concentrations of 5 ϫ 10 Ϫ3 m decreased pancreatic glucokinase mRNA levels. These researchers, however, did not analyze other concentrations of the nucleotide and did not analyze the effect on glucokinase enzymatic activity or promoter activity.
We also demonstrated the ability of cAMP to activate the Ϫ1000 kb ␤-cell glucokinase promoter, providing further evidence that cAMP affects pancreatic glucokinase gene transcription. However, we could not identify any cAMP response element consensus sequence on the Ϫ1000 kb ␤ cell glucokinase promoter. Further studies will be required to determine the precise mechanisms that mediate the cAMP effect on the pancreatic glucokinase promoter.
We and others have previously demonstrated that glucokinase isoenzymes are regulated differently in the pancreatic ␤-cell and the liver (2, 19, 20) , supporting the concept that alternate promoters and first exons confer differential isoenzyme regulation. In the pancreatic ␤-cell, glucose acts as a positive regulator of glucokinase enzyme activity (2) . Posttranscriptional regulation has been invoked to explain glucose induction of glucokinase in the ␤-cell (19) . In the liver, insulin, not glucose, is the positive stimulus for glucokinase activity and gene transcription (2, (15) (16) (17) . Previously (20) we have shown that, in contrast to the stimulatory effect of thyroid hormone (T 3 ) on hepatic glucokinase (36 -38) , the activity of pancreatic glucokinase is not affected by T 3 despite the negative effect of T 3 on glucokinase mRNA levels. The development of the enzyme in the islet and that in the liver also differ. In the pancreatic ␤-cell, glucokinase is already present during fetal life (34) , whereas in the liver glucokinase appears 2 weeks after birth (39, 40) . The repression of glucokinase gene transcription in response to glucagon via cAMP is an essential feature of hepatic glucokinase regulation (15, 17, 23) , but in this work we demonstrate that cAMP produces an increase in pancreatic glucokinase activity and expression.
Several studies have investigated the mechanisms by which an increase in cAMP potentiates glucose-induced insulin secretion. Increased rates of phosphorylation of ion channels in the ␤-cell membrane via cAMP-dependent protein kinase A may be a mechanism leading to increased ␤-cell sensitivity to primary stimuli (41) (42) (43) (44) . In addition, cAMP has been shown to promote insulin release by an action distal to the regulatory steps of the secretory machinery (44 -46 ). It appears, however, that increases in glucokinase gene expression also may contribute to the potentiation of glucoseinduced insulin secretion induced by the cyclic nucleotide. Further studies will be required to determine the relative contribution of increased glucokinase activity to the overall effects of cAMP on insulin secretion.
